Accumulating evidence support that c-Abl inhibition could be one of therapeutic options to mitigate the pathology of ALS [17,18,19], suggesting that c-Abl can closely regulate the pathological downstream processes in ALS. Here, ABL1 is linked to amyotrophic lateral sclerosis.